Status:
COMPLETED
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
Lead Sponsor:
Pfizer
Conditions:
Malaria
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To compare Azithromycin plus Chloroquine versus Mefloquine to treat uncomplicated plasmodium falciparum malaria.
Eligibility Criteria
Inclusion
- Females and males 18 years of age and older with uncomplicated, symptomatic malaria as as indicated by the presence of both of the following:
- Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites
- Documented fever (38.5 C/101.3 F rectal or tympanic; 37.5 C/99.5 F axillary or 38 C/100.4 F oral) or history of fever (as reported by subject) within the prior 24 hours.
Exclusion
- Severe or complicated malaria.
- Pregnant or breast-feeding women.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
397 Patients enrolled
Trial Details
Trial ID
NCT00367653
Start Date
November 1 2006
End Date
September 1 2007
Last Update
September 16 2008
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ouagadougou, West Africa, Burkina Faso, 01
2
Pfizer Investigational Site
Nouna, Burkina Faso
3
Pfizer Investigational Site
Navrongo, West Africa, Ghana
4
Pfizer Investigational Site
Kisumu, Kisumu County, Kenya, 40100